Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels

Vincenzo Spagnuolo, Gianluca Gentilini, Anna De Bona, Laura Galli, Caterina Uberti-Foppa, Armando Soldarini, Fernanda Dorigatti, Elena Seminari

Research output: Contribution to journalArticle

Abstract

Acute liver toxicity is a frequent adverse event that occurs during antiretroviral therapy and was observed in 6-30% of the patients on treatment, especially in presence of HCV coinfection (Cooper et al., 2002, Maida et al., 2006, Sulkowski et al., 2000). A correlation between HCV-associated liver-fibrosis severity and the risk of HAART associated hepatoxicity has been demonstrated (Aranzabal et al., 2005, Sulkowski et al., 2004). This high liver toxicity rate might be due to increased drug exposure in patients with liver disease (Veronese et al., 2000). It has been reported that patients with chronic hepatitis C show significantly reduced CPY3A4 and CYP2D6 activity in comparison with healthy volunteers (Becquemont et al., 2002). The aim of this study was to evaluate the liver function tests in HCV-co-infected patients treated with fos-amprenavir and ritonavir.

Original languageEnglish
Pages (from-to)279-282
Number of pages4
JournalNew Microbiologica
Volume30
Issue number3
Publication statusPublished - Jul 2007

Keywords

  • Cirrhosis
  • Fos-amprenavir
  • HCV-infection

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Fingerprint Dive into the research topics of 'Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels'. Together they form a unique fingerprint.

  • Cite this